Header cover image

UNH: Valuations Seem Lofty for this Managed Healthcare Giant

WA

WallStreetWontons

Invested

Community Contributor

Published

December 14 2023

Updated

July 11 2024

Narratives are currently in beta

Catalysts

Products and Services:

Industry Tailwinds:

Assumptions

If the forward estimates compounds at around 10%, we can expect the revenue to exceed $600 billion in the next five years.

Net profit margins have averaged 4 to 5% in the last five years. We could estimate the similar rate for the next five years where earnings could reach $24 billion.

Risks

While UNH has several growth catalysts, there are risks associated with their execution:

  • Regulatory Changes: Healthcare regulations can significantly affect UNH’s operations and profitability. Changes in policies related to Medicare, Medicaid, or the Affordable Care Act (ACA) could impact revenue and costs.
  • Market Competition: Intense competition in the healthcare industry may affect UNH’s market share, pricing power, and profitability.
  • Technology Adoption: Rapid technological advancements require UNH to adapt and invest in digital health solutions. Failure to do so could hinder growth.
  • Mergers and Acquisitions: UNH’s acquisition strategy carries integration risks. Poorly executed acquisitions may not yield expected synergies.
  • Healthcare Trends: Shifts in consumer preferences, telehealth adoption, and preventive care could impact UNH’s business model.

Regulatory and Competitor Risks:

  • Regulatory Risks:
    • Government Policies: Changes in government policies related to healthcare reimbursement, drug pricing, or insurance regulations can impact UNH’s financials.
    • Legal Challenges: Litigation risks (e.g., antitrust, fraud, or privacy-related lawsuits) could affect UNH’s reputation and financial stability.

Competitor Risks:

  • Other Insurers: Rival insurers may offer competitive plans, affecting UNH’s market share.
  • Pharmacy Benefit Managers (PBMs): PBMs like CVS Health and Express Scripts compete with OptumRx, UNH’s pharmacy services arm.
  • Healthcare Providers: Hospitals and healthcare systems may negotiate better terms, impacting UNH’s costs.

Valuation

Revenue and Profit Margins:

  • 3 Years: Assuming continued growth, UNH’s revenue could reach approximately $502 billion in 3 years.
    • Profit margins may remain stable or improve slightly, driven by cost management and operational efficiency.
  • 5 Years: Projecting moderate growth, revenue might be around $605 billion, with profit margins showing incremental improvement.
  • 10 Years: Long-term forecasts are more speculative, but assuming sustained growth, revenue could exceed $967 billion, and profit margins may continue to expand.

Valuation Multiple:

  • Valuation multiples (such as price-to-earnings ratio) depend on investor sentiment, market conditions, and industry trends.
  • Historically, UNH has traded at a P/E ratio of 15–20x.
  • In the future, if UNH maintains strong financials and growth, the P/E ratio could remain in a similar range.
  • However, external factors (e.g., economic cycles, regulatory changes) can impact valuation multiples.

How well do narratives help inform your perspective?

Disclaimer

The user WallStreetWontons has a position in NYSE:UNH. Simply Wall St has no position in any of the companies mentioned. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Fair Value

US$383.5

43.1% OVERVALUED

WallStreetWontons's Fair Value

Future estimation in
PastFuture0100b200b300b400b500b20142016201820202022202420262027Revenue US$502.5bEarnings US$20.3b
% p.a.
Decrease
Increase

Current revenue growth rate

6.98%

Healthcare Services revenue growth rate

0.27%

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.